CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 23 enrolled
Drug / intervention
Genistein vs Risedronatedietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00244907
NCT00244907Phase 1Completed
CompareCT.gov

Metabolism and Bone Health

Purdue University·interventional·Posted Oct 27, 2005·Updated May 4, 2018

In Brief

A Phase 1 clinical trial evaluating Genistein vs Risedronate for Osteoporosis and Osteopenia. Completed, enrolled 23 participants across 1 site.

Detailed Summary

Estrogen is a hormone that helps prevent calcium loss and bone breakdown. During menopause, estrogen levels decrease. Insufficient amounts of estrogen may lead to bone loss and possibly osteoporosis. Isoflavones are natural compounds found in soy plants that may help provide protection against bone loss. This study will evaluate the effect of soy isoflavones on calcium absorption and bone loss in post menopausal women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Osteopenia
CountriesUnited States
CollaboratorsNational Center for Complementary and Integrative Health (NCCIH), Office of Dietary Supplements (ODS)

Timeline

Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 27, 2005
Enrollment StartJan 1, 2006
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 20.7 years ago

Interventions

Genistein vs Risedronatedietary

Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)